Related references
Note: Only part of the references are listed.Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?
Thanarat Salahong et al.
VIRUSES-BASEL (2021)
UHRF1 Suppresses HIV-1 Transcription and Promotes HIV-1 Latency by Competing with p-TEFb for Ubiquitination-Proteasomal Degradation of Tat
Taizhen Liang et al.
MBIO (2021)
CPI-637 as a Potential Bifunctional Latency-Reversing Agent That Targets Both the BRD4 and TIP60 Proteins
Tengyi Zheng et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2021)
Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-κB Pathways Mediated by Heat Shock Response
Wen Peng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs
Amina Ait-Ammar et al.
FRONTIERS IN MICROBIOLOGY (2020)
Potential Adverse Effects of Resveratrol: A Literature Review
Abdullah Shaito et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Zein nanoparticles as low-cost, safe, and effective carriers to improve the oral bioavailability of resveratrol
Rute Nunes et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2020)
Gliotoxin, identified from a screen of fungal metabolites, disrupts 7SK snRNP, releases P-TEFb, and reverses HIV-1 latency
Mateusz Stoszko et al.
SCIENCE ADVANCES (2020)
The African natural product knipholone anthrone and its analogue anthralin (dithranol) enhance HIV-1 latency reversal
Khumoekae Richard et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo
Andrew Timmons et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Influence of Resveratrol on the Cardiovascular Health Effects of Chronic Kidney Disease
Jenn-Yeu Song et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Therapeutic potential of resveratrol against emerging respiratory viral infections
Simone Filardo et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Resveratrol, cancer and cancer stem cells: A review on past to future
Vasanth K. Bhaskara et al.
CURRENT RESEARCH IN FOOD SCIENCE (2020)
A computational study of Tat-CDK9-Cyclin binding dynamics and its implication in transcription-dependent HIV latency
Huiwen Wang et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2020)
The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation
Xuan-xuan Zhang et al.
ACTA PHARMACOLOGICA SINICA (2019)
BRD4 inhibition attenuates inflammatory response in microglia and facilitates recovery after spinal cord injury in rats
Jianle Wang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Health benefits of resveratrol: Evidence from clinical studies
Akhand Pratap Singh et al.
MEDICINAL RESEARCH REVIEWS (2019)
HIV shock and kill therapy: In need of revision
Erik Abner et al.
ANTIVIRAL RESEARCH (2019)
A novel bromodomain inhibitor, CPI-203, serves as an HIV-1 latency-reversing agent by activating positive transcription elongation factor b
Taizhen Liang et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infections
He Yang et al.
ANTIVIRAL RESEARCH (2019)
IP-10 is highly involved in HIV infection
Jie Lei et al.
CYTOKINE (2019)
Novel Latency Reversal Agents for HIV-1 Cure
Adam M. Spivak et al.
ANNUAL REVIEW OF MEDICINE, VOL 69 (2018)
Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication
Grant R. Campbell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Structure-Based Discovery and Optimization of Benzo[&ITd&IT]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC)
Maofeng Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
HIV replication is associated to inflammasomes activation, IL-1β, IL-18 and caspase-1 expression in GALT and peripheral blood
Manuel Geronimo Feria et al.
PLOS ONE (2018)
Barriers for HIV Cure: The Latent Reservoir
Sergio Castro-Gonzalez et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2018)
RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency
Catalina Mendez et al.
RETROVIROLOGY (2018)
HIV-1 Latency-Reversing Agents Prostratin and Bryostatin-1 Induce Blood-Brain Barrier Disruption/Inflammation and Modulate Leukocyte Adhesion/Transmigration
Clelia Dental et al.
JOURNAL OF IMMUNOLOGY (2017)
Resveratrol Reactivates Latent HIV through Increasing Histone Acetylation and Activating Heat Shock Factor 1
Xiaoyun Zeng et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2017)
Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui
Pengfei Wang et al.
SCIENTIFIC REPORTS (2017)
Targeting TNF-Alpha in HIV-1 Infection
Amit Kumar et al.
CURRENT DRUG TARGETS (2016)
Are T cells the only HIV-1 reservoir?
Abraham Joseph Kandathil et al.
RETROVIROLOGY (2016)
Broad activation of latent HIV-1 in vivo
Kirston Barton et al.
NATURE COMMUNICATIONS (2016)
Strategies to target non-T-cell HIV reservoirs
Jonah B. Sacha et al.
CURRENT OPINION IN HIV AND AIDS (2016)
The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb
Panpan Lu et al.
SCIENTIFIC REPORTS (2016)
Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents
Heloise M. Delagreverie et al.
OPEN FORUM INFECTIOUS DISEASES (2016)
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations
Gregory M. Laird et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat
Rikke Olesen et al.
JOURNAL OF VIROLOGY (2015)
Enigma of HIV-1 latent infection in astrocytes: an in-vitro study using protein kinase C agonist as a latency reversing agent
Ashok Chauhan
MICROBES AND INFECTION (2015)
An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression
Gilles Darcis et al.
PLOS PATHOGENS (2015)
Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation
Guochun Jiang et al.
PLOS PATHOGENS (2015)
Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling
Guochun Jiang et al.
AIDS (2014)
BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma
Joydeep Bhadury et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Reactivation of latent HIV-1 by new semi-synthetic ingenol esters
Diego Pandelo Jose et al.
VIROLOGY (2014)
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism
Daniela Boehm et al.
CELL CYCLE (2013)
BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses
Anna C. Belkina et al.
JOURNAL OF IMMUNOLOGY (2013)
Cyclin T1 and CDK9 T-Loop Phosphorylation Are Downregulated during Establishment of HIV-1 Latency in Primary Resting Memory CD4+ T Cells
Sona Budhiraja et al.
JOURNAL OF VIROLOGY (2013)
The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation
Zichong Li et al.
NUCLEIC ACIDS RESEARCH (2013)
CTIP2 is a negative regulator of P-TEFb
Thomas Cherrier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+T Cells from Aviremic Patients
Celsa A. Spina et al.
PLOS PATHOGENS (2013)
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
N. M. Archin et al.
NATURE (2012)
Phosphatase PPM1A negatively regulates P-TEFb function in resting CD4T+ T cells and inhibits HIV-1 gene expression
Sona Budhiraja et al.
RETROVIROLOGY (2012)
Establishment of HIV Latency in Primary CD4+ Cells Is due to Epigenetic Transcriptional Silencing and P-TEFb Restriction
Mudit Tyagi et al.
JOURNAL OF VIROLOGY (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Bryostatin Modulates Latent HIV-1 Infection via PKC and AMPK Signaling but Inhibits Acute Infection in a Receptor Independent Manner
Rajeev Mehla et al.
PLOS ONE (2010)
PP2B and PP1α cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling
Ruichuan Chen et al.
GENES & DEVELOPMENT (2008)
CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection:: a novel model of HIV-1 latency
Suha Saleh et al.
BLOOD (2007)
Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription
Dwayne A. Bisgrovet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Inhibition of HIV-I replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex
Sebastian Biglione et al.
RETROVIROLOGY (2007)
Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein brd4
ZY Yang et al.
MOLECULAR CELL (2005)
High absorption but very low bioavailability of oral resveratrol in humans
T Walle et al.
DRUG METABOLISM AND DISPOSITION (2004)
A human immunodeficiency virus type 1 tat-like arginine-rich RNA-binding domain is essential for HEXIM1 to inhibit RNA polymerase II transcription through 7SK snRNA-Mediated inactivation of P-TEFb
JHN Yik et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro
A Jordan et al.
EMBO JOURNAL (2003)
Share Paper
